| Source: |
| Type: |
| Tumor cell proliferation is a key characteristic of cancer. It refers to the rapid and uncontrolled growth of cells that can lead to the formation of tumors. |
| Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression. TP53 is the most commonly mutated gene in human cancer. HH↑, GLI-1↑, SHH↑ P53↓ The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca. It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma. Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer. It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress. Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC. |
| 4435- | AgNPs, | Gluc, | Glucose-Functionalized Silver Nanoparticles as a Potential New Therapy Agent Targeting Hormone-Resistant Prostate Cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 4808- | ASTX, | Anti-Tumor Effects of Astaxanthin by Inhibition of the Expression of STAT3 in Prostate Cancer |
| - | in-vitro, | Pca, | DU145 | - | in-vivo, | NA, | NA |
| 147- | ATG, | EGCG, | CUR, | Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | MCF-7 |
| 2602- | Ba, | Downregulation of ZFX is associated with inhibition of prostate cancer progression by baicalein |
| - | in-vitro, | Pca, | NA | - | in-vivo, | Pca, | NA |
| 5653- | BNL, | Borneol hinders the proliferation and induces apoptosis through the suppression of reactive oxygen species-mediated JAK1 and STAT-3 signaling in human prostate cancer cells |
| - | in-vitro, | Pca, | PC3 |
| 3512- | Bor, | Activation of the EIF2α/ATF4 and ATF6 Pathways in DU-145 Cells by Boric Acid at the Concentration Reported in Men at the US Mean Boron Intake |
| - | in-vitro, | Pca, | DU145 |
| 3513- | Bor, | Boric Acid Activation of eIF2α and Nrf2 Is PERK Dependent: a Mechanism that Explains How Boron Prevents DNA Damage and Enhances Antioxidant Status |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Nor, | MEF |
| 705- | Bor, | Boric acid inhibits human prostate cancer cell proliferation |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 710- | Bor, | Boric acid inhibits stored Ca2+ release in DU-145 prostate cancer cells |
| - | in-vitro, | Pca, | DU145 |
| 4620- | Bor, | BTZ, | Boron Compounds in the Breast Cancer Cells Chemoprevention and Chemotherapy |
| - | Review, | Var, | NA | - | Review, | Arthritis, | NA | - | Review, | Pca, | NA |
| 1449- | Bos, | Chemo, | Anti-proliferative, Pro-apoptotic, and Chemosensitizing Potential of 3-Acetyl-11-keto-β-boswellic Acid (AKBA) Against Prostate Cancer Cells |
| - | in-vitro, | Pca, | PC3 |
| 145- | CA, | CUR, | The anti-cancer effects of carotenoids and other phytonutrients resides in their combined activity |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 | - | in-vitro, | PC, | DU145 |
| 5867- | CA, | Inhibitory effects of rosemary extracts, carnosic acid and rosmarinic acid on the growth of various human cancer cell lines |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Liver, | Hep3B | - | in-vitro, | AML, | K562 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | BC, | MDA-MB-231 |
| 5828- | CAP, | Capsaicin: a novel radio-sensitizing agent for prostate cancer |
| - | vitro+vivo, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 2013- | CAP, | Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vivo, | NA, | NA |
| 5761- | CAPE, | Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of AMPK and Akt signaling networks |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 5940- | Cela, | Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway |
| - | in-vivo, | Pca, | PC3 |
| 1580- | Citrate, | Citrate activates autophagic death of prostate cancer cells via downregulation CaMKII/AKT/mTOR pathway |
| - | in-vitro, | Pca, | PC3 | - | in-vivo, | PC, | NA | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | WPMY-1 |
| 137- | CUR, | Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling |
| - | in-vitro, | Pca, | DU145 |
| 146- | CUR, | EGCG, | Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 152- | CUR, | Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer |
| - | in-vivo, | Pca, | NA |
| 133- | CUR, | Curcumin inhibits prostate cancer by targeting PGK1 in the FOXD3/miR-143 axis |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 14- | CUR, | Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 Pathway |
| - | vitro+vivo, | Pca, | PC3 |
| 165- | CUR, | Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP |
| 461- | CUR, | Curcumin inhibits prostate cancer progression by regulating the miR-30a-5p/PCLAF axis |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 181- | CUR, | The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo |
| - | vitro+vivo, | Pca, | DU145 |
| 168- | CUR, | Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism |
| - | in-vitro, | Pca, | PC3 |
| 24- | EGCG, | GEN, | QC, | Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin |
| - | in-vitro, | Pca, | 22Rv1 |
| 2499- | Fenb, | VitE, | Effects of fenbendazole and vitamin E succinate on the growth and survival of prostate cancer cells |
| - | in-vitro, | Pca, | PC3 |
| 1958- | GamB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| - | in-vitro, | Pca, | NA | - | in-vivo, | NA, | NA |
| 2060- | GamB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 4637- | HT, | Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells |
| - | in-vitro, | Nor, | RWPE-1 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PC3 |
| 4639- | HT, | Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 4780- | Lyco, | Potential inhibitory effect of lycopene on prostate cancer |
| - | Review, | Pca, | NA |
| 5186- | PEITC, | Phenethyl Isothiocyanate inhibits STAT3 activation in prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 5209- | PI, | Piperine depresses the migration progression via downregulating the Akt/mTOR/MMP-9 signaling pathway in DU145 cells |
| - | in-vitro, | Pca, | DU145 |
| 5164- | PLB, | Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2 |
| - | vitro+vivo, | CRC, | NA | - | in-vitro, | Pca, | NA |
| 66- | QC, | Emerging impact of quercetin in the treatment of prostate cancer |
| - | Review, | Pca, | NA |
| 96- | QC, | docx, | Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways |
| - | vitro+vivo, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 88- | QC, | PacT, | Quercetin Enhanced Paclitaxel Therapeutic Effects Towards PC-3 Prostate Cancer Through ER Stress Induction and ROS Production |
| - | vitro+vivo, | Pca, | PC3 |
| 82- | QC, | ATG, | Arctigenin in combination with quercetin synergistically enhances the anti-proliferative effect in prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP |
| 79- | QC, | Chemopreventive Effect of Quercetin in MNU and Testosterone Induced Prostate Cancer of Sprague-Dawley Rats |
| - | in-vivo, | Pca, | NA |
| 3373- | QC, | The Effect of Quercetin in the Yishen Tongluo Jiedu Recipe on the Development of Prostate Cancer through the Akt1-related CXCL12/ CXCR4 Pathway |
| - | in-vitro, | Pca, | DU145 |
| 3029- | RosA, | Rosmarinic Acid, a Component of Rosemary Tea, Induced the Cell Cycle Arrest and Apoptosis through Modulation of HDAC2 Expression in Prostate Cancer Cell Lines |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 4908- | Sal, | Salinomycin triggers prostate cancer cell apoptosis by inducing oxidative and endoplasmic reticulum stress via suppressing Nrf2 signaling |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 3192- | SFN, | Transcriptome analysis reveals a dynamic and differential transcriptional response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in chemoprevention |
| - | in-vitro, | Pca, | PC3 |
| - | in-vitro, | Pca, | NA |
| 2446- | SFN, | CAP, | The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor |
| - | in-vitro, | Pca, | LNCaP |
| 1469- | SFN, | Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | Pca, | NA |
| 1453- | SFN, | Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7 |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:22 Cells:% prod#:% Target#:327 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid